Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S.
College of American Pathologists (CAP) Accreditation Signifies the Highest Standards in Laboratory Practice Golden, Colorado — November 28, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision oncology company with a novel phosphoprotein-based assay for breast cancer, today announced that the Company has received College of American Pathologists (“CAP”) Accreditation for its […]
His Excellency Ahmed Elmetwally exclusively invites Infusion 51a Executives to be part of the International Indo-Arab Conference in Medicine 2022
Dubai, UAE, November 27th, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East this year attended on Sunday, November 27th the International Indo-Arab Conference in Medicine (IIAC-M) 2022 in Dubai, UAE, by exclusive invitation from His Excellency Ahmed Elmetwally, the current Ministry of Presidential […]
Infusion 51a Executives attend the 10th Emirates Oncology Conference in Abu Dhabi, UAE
Abu Dhabi, UAE, November 26th, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East this year, attended on Saturday, November 26th the 10th Emirates Oncology Conference in Abu Dhabi, UAE, held at the Conrad Etihad Towers. The 10th Emirates Oncology Conference is a three-day […]
Infusion 51a Executives Participate in the 5th Annual Combined Gulf Cancer Conference in Sharjah, UAE
Sharjah, UAE, November 23rd, 2022 – Infusion 51a, an impact investment fund based in the US in its fourth trip to the Middle East this year, attended on November 21-23 the 5th Annual Combined Gulf Cancer Conference (CGCC) in JRCC, Sharjah. The conference, which focuses on the cancer spectrum in the Gulf region, was hosted […]